| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 07/04/2002 | CA2436739A1 Combination agent |
| 07/04/2002 | CA2432715A1 Novel atopic dermatitis-associated gene and proteins |
| 07/04/2002 | CA2432570A1 New clinical treatment |
| 07/04/2002 | CA2431916A1 New therapeutic uses of smr1 peptides |
| 07/04/2002 | CA2431913A1 Modulation of smr1-nep interactions in cns disorders giving rise to mental disorders |
| 07/03/2002 | EP1219638A2 G-protein coupled receptors having homology to the P2Y purinoreceptor 1 (P2Y1) |
| 07/03/2002 | EP1219612A1 2-imino-1,3-thiazine derivatives |
| 07/03/2002 | EP1219600A1 Prostaglandin derivatives |
| 07/03/2002 | EP1218509A2 Fibroblast growth factor-like polypeptides |
| 07/03/2002 | EP1218491A1 Dna encoding a human subunit 5-ht3-c of the 5-ht3 serotonin receptor |
| 07/03/2002 | EP1218412A2 Human g-protein coupled receptor |
| 07/03/2002 | EP1218408A1 32 human secreted proteins |
| 07/03/2002 | EP1218372A1 Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases |
| 07/03/2002 | EP1218369A1 INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES |
| 07/03/2002 | EP1218025A1 Use of mullerian inhibiting substance for treating excess androgen states |
| 07/03/2002 | EP1218020A1 Treatment of diabetic nephropathy and microalbuminuria |
| 07/03/2002 | EP1217998A2 Use of (+)-tramadol, o-demethyltramadol or (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol or (+)-o-desmethyl-n-mono-desmethyl-tramadol for treating urinary incontinence |
| 07/03/2002 | EP1077912B1 Novel derivatives of 3,3-diphenylpropylamines |
| 07/03/2002 | EP0754054B1 Antirestenosis protein |
| 07/03/2002 | CN1357038A Combination of lactic acid bacteria and its use for prevention and/or treatment of infections and inflammatory conditions |
| 07/03/2002 | CN1357002A Compositions for treating inflammatory response |
| 07/03/2002 | CN1356991A Quinoline and quinoxaline compounds as PDGF-R and/or LCD tyrosine kinase inhibitors |
| 07/03/2002 | CN1356911A Method for treatment of fibrosis using antagonist of integrin alpha-4 subunit |
| 07/03/2002 | CN1356902A IL-8 receptor antagonists |
| 07/03/2002 | CN1356894A Transdermal therapeutic system (TTS) contg. tolterodine |
| 07/03/2002 | CN1356118A Capsule 'Qianliean' for treating prostatitis |
| 07/03/2002 | CN1356117A Capsule 'Tangniaoshenkang' for treating diabetes |
| 07/02/2002 | US6414153 1-phenylpydrrolidin-2-ones and -thiones and 1-(4-pyridyl)pydrrolidin-2-ones and -thiones which are useful in the treatment of inflammatory disease |
| 07/02/2002 | US6414148 Produce antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals |
| 07/02/2002 | US6414013 Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention |
| 07/02/2002 | US6413995 Immunomodulators |
| 07/02/2002 | US6413991 Antidiabetic agents; dietetics |
| 07/02/2002 | US6413988 Prucalopride oral solution |
| 07/02/2002 | US6413984 8-(heterocyclylmethyl)quinoline derivatives for treating urinary incontinence |
| 07/02/2002 | US6413979 Substituted 5-(2,2-difluoro-1,3-benzodioxol-5-yl) cyclopentenopyridine derivative |
| 07/02/2002 | US6413977 Chromeno[4,3,2-DE]isoquinolines as potent dopamine receptor ligands |
| 07/02/2002 | US6413971 Antiproliferative, -carcinogenic, -tumor and -diabetic agents; binding to or modulating the human kinase insert-domain-containing receptor (kdr) or the murine fetal liver kinase 1 (flk-1) receptor; vasculogenesis; angiogenesis |
| 07/02/2002 | US6413965 Selective cox-2 and an aldose reductase inhibitor; neuropathy, nephropathy, retinopathy and cardiomyopathy; avoiding side effects such as gastric and renal toxicity |
| 07/02/2002 | US6413964 14-amino-14-(1-methyl-1h-imidazol-5-yl)-8-oxa-2-thia-1,18 -diazatetracyclo(16.2.2.1(3,7).1(9,13))tetracosa-3(24),4,6, 9(23),10,12-hexaene-10-carbonitrile 2,2-dioxide, for example; use in radiotherapy, chemotherapy as sensitizer |
| 07/02/2002 | US6413963 Alpha, beta-integrin inhibitors used in the treatment of multiple sclerosis, atherosclerosis, asthma and inflammatory bowel disease |
| 07/02/2002 | US6413731 Methods of screening for compounds which bind to a human SNORF36A receptor |
| 07/02/2002 | CA2047283C Pyrazolopyridine compound and processes for preparation thereof |
| 06/27/2002 | WO2002050284A2 Oxidoreductases |
| 06/27/2002 | WO2002050283A2 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 06/27/2002 | WO2002050097A2 Anti-allergic complex molecules |
| 06/27/2002 | WO2002050070A2 Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists |
| 06/27/2002 | WO2002050066A2 Pyrazole compounds useful as protein kinase inhibitors |
| 06/27/2002 | WO2002050065A2 Pyrazole compounds useful as protein kinase inhibitors |
| 06/27/2002 | WO2002050044A1 Novel 2,3-benzodiazepine derivatives and pharmaceutical compositions containing the same as the active ingredient |
| 06/27/2002 | WO2002050039A1 Urea and urethane derivatives as integrin inhibitors |
| 06/27/2002 | WO2002050033A1 Benzo(f) isoindol derivatives and their use as ep4 receptor ligands |
| 06/27/2002 | WO2002050032A1 Naphthalene derivatives which bind to the ep4 receptor |
| 06/27/2002 | WO2002050028A2 Substituted benzoindoles as spla2 inhibitors |
| 06/27/2002 | WO2002050021A1 Nitric oxide synthase inhibitor phosphate salt |
| 06/27/2002 | WO2002050019A2 Diamines as modulators of chemokine receptor activity |
| 06/27/2002 | WO2002049993A2 High affinity small molecule c5a receptor modulators |
| 06/27/2002 | WO2002049714A2 Electrically responsive promoter system |
| 06/27/2002 | WO2002049669A2 Electrically responsive promoter system |
| 06/27/2002 | WO2002049651A1 Pharmaceutical formulation containing pyrazolo[4,3-d]pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives |
| 06/27/2002 | WO2002049650A2 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives |
| 06/27/2002 | WO2002049649A2 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2) |
| 06/27/2002 | WO2002049646A1 Therapeutic combination of amlodipine and benazepril/benazeprilat |
| 06/27/2002 | WO2002049645A1 Therapeutic combination of amlodipine and benazepril |
| 06/27/2002 | WO2002049634A2 Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect |
| 06/27/2002 | WO2002030393A3 Polymeric delivery formulations of leuprolide with improved efficacy |
| 06/27/2002 | WO2002030353A3 NF-λB INHIBITORS |
| 06/27/2002 | WO2002020822A3 Biopanning and rapid analysis of selective interactive ligands (brasil) |
| 06/27/2002 | WO2002020566A3 NOVEL MMP-2 DERIVATIVES FOR USE AS INHIBITORS OF INTEGRIN αVβ¿3? |
| 06/27/2002 | WO2002008231A3 Biologically active macrolides, compositions, and uses thereof |
| 06/27/2002 | WO2001092267A3 Dihydropyridine compounds for the inhibition of calcium-influx |
| 06/27/2002 | WO2001077375A3 Diagnosis of diseases associated with gene regulation |
| 06/27/2002 | WO2001076584A3 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases |
| 06/27/2002 | WO2001072994A3 Human urothelial cell specific uroplakin transcriptional regulatory sequences, vectors comprising the same, and methods of use thereof |
| 06/27/2002 | US20020082435 For use in cancer therapy |
| 06/27/2002 | US20020082420 Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
| 06/27/2002 | US20020082388 Polypeptide for use in the treatment, diagnosis and prevention of cancer, nervous system and developmental disorders |
| 06/27/2002 | US20020082292 Agonists of peroxisome proliferator activated receptor (PPAR) alpha and/or gamma |
| 06/27/2002 | US20020082269 Purine-2,6-dione based compounds as receptor binding assay probes and pharmaceuticals; high potency and affinity with water solubility |
| 06/27/2002 | US20020082266 Method of treatment using phenyl and biaryl derivatives as prostaglandin E inhibitors and compounds useful therefore |
| 06/27/2002 | US20020082256 Compounds useful as anti-inflammatory agents |
| 06/27/2002 | US20020082242 Compositions and methods of double-targeting virus infections and cancer cells |
| 06/27/2002 | US20020082231 Utilizing ratC polypeptides to screen for antibacterial compounds |
| 06/27/2002 | US20020082202 Screening methods using ligands of the neutropeptide receptor HFGAN72 |
| 06/27/2002 | US20020081659 Nucleic acids, proteins and antibodies |
| 06/27/2002 | US20020081607 Four disulfide core domain-containing (FDCD) polynucleotides, polypeptides, and antibodies |
| 06/27/2002 | CA2436699A1 Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists |
| 06/27/2002 | CA2432908A1 Diamines as modulators of chemokine receptor activity |
| 06/27/2002 | CA2432879A1 Anti-allergic complex molecules |
| 06/27/2002 | CA2432638A1 Therapeutic combination of amlodipine and benazepril |
| 06/27/2002 | CA2432310A1 Electrically responsive promoter system |
| 06/27/2002 | CA2432282A1 Therapeutic combination of amlodipine and benazepril/benazeprilat |
| 06/27/2002 | CA2431964A1 Conjugates of erythropoietin (pep) with polyethylene glycol (peg) |
| 06/27/2002 | CA2431147A1 Pharmaceutical formulation comprising thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2) |
| 06/27/2002 | CA2431139A1 Oxidoreductases |
| 06/27/2002 | CA2431077A1 Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives |
| 06/27/2002 | CA2431074A1 Pharmaceutical formulation comprising thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (1) |
| 06/27/2002 | CA2431023A1 Substituted benzoindoles as spla2 inhibitors |
| 06/27/2002 | CA2430754A1 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 06/27/2002 | CA2430595A1 Dissociated glucocorticoid receptor antagonists for the treatment of glucocorticoid associated side-effect |
| 06/26/2002 | EP1216707A1 New therapeutic uses of a SMR-1-peptide |